Complicated Intra-Abdominal Infections (cIAIs) Pipeline Analysis | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies

April 24 20:39 2023
Complicated Intra-Abdominal Infections (cIAIs) Pipeline Analysis | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Complicated Intra-Abdominal Infections (cIAIs) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Complicated Intra-Abdominal Infections (cIAIs) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Complicated Intra-Abdominal Infections Market. 

The Complicated Intra-Abdominal Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Complicated Intra-Abdominal Infections (cIAIs) Pipeline Analysis

Complicated Intra-Abdominal Infections (cIAIs) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Complicated Intra-Abdominal Infections and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Complicated Intra-Abdominal Infections market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

The Complicated Intra-Abdominal Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • intravitreal

  • Subretinal

  • Topical

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Ongoing Clinical & Commercial Activities will Affect the Complicated Intra-Abdominal Infections Therapeutic Segment @

Complicated Intra-Abdominal Infections (cIAIs) Therapeutics Landscape

There are approx. 15+ key companies developing therapies for Complicated Intra-Abdominal Infections. Currently, AbbVie is leading the therapeutics market with its Complicated Intra-Abdominal Infections drug candidates in the most advanced stage of clinical development.

The Leading Players in the Complicated Intra-Abdominal Infections (cIAIs) Therapeutics  Market Include:

  • AbbVie

  • AiCuris

  • Allecra

  • AstraZeneca

  • Iterum Therapeutics

  • MerLion Pharmaceuticals

  • Nosopharm

  • Novartis

  • Pfizer

  • Shionogi

And Many Others

Complicated Intra-Abdominal Infections Emerging and Market Drugs Covered in the Report Include:

  • Finafloxacin

  • AIC499

  • LYS-228

  • Cefepime/AAI101

  • Avibactam/aztreonam

  • Cefiderocol

  • Sulopenem etzadroxil

  • NOSO-502

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Complicated Intra-Abdominal Infections Current Treatment Patterns

4. Complicated Intra-Abdominal Infections – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Complicated Intra-Abdominal Infections Late Stage Products (Phase-III)

7. Complicated Intra-Abdominal Infections Mid-Stage Products (Phase-II)

8. Complicated Intra-Abdominal Infections Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Complicated Intra-Abdominal Infections Discontinued Products

13. Complicated Intra-Abdominal Infections Product Profiles

14. Key Companies in the Complicated Intra-Abdominal Infections Market

15. Key Products in the Complicated Intra-Abdominal Infections Therapeutics Segment

16. Dormant and Discontinued Products

17. Complicated Intra-Abdominal Infections Unmet Needs

18. Complicated Intra-Abdominal Infections Future Perspectives

19. Complicated Intra-Abdominal Infections Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Services and Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

view more articles

About Article Author